Edition:
India

People: Merit Medical Systems Inc (MMSI.OQ)

MMSI.OQ on NASDAQ Stock Exchange Global Select Market

58.82USD
2:29am IST
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$58.83
Open
$58.27
Day's High
$59.35
Day's Low
$57.83
Volume
72,953
Avg. Vol
133,332
52-wk High
$66.28
52-wk Low
$40.70

Liu, David 

Dr. David Ming-Teh Liu is Director of the Company. He is an Interventional Radiologist with the current appointment of Clinical Associate Professor of Radiology at the University of British Columbia, a position he has held since 2008. Dr. Liu Interventional radiologist (certified in the U.S. and Canada), practicing at the Vancouver General Hospital, University of British Columbia Hospital, and BC Cancer Agency (with cross appointment in surgery department), 2008 to present. He is Clinical Associate Professor of Radiology at the University of British Columbia, 2008 to present, Medical Director at Eva Vein Care (team of physicians specializing in diagnostic assessment, endovascular therapy and interventional radiology), 2012 to present, Co-founder and co-chair of the international liver cancer symposium, SHOW, Credited with 7 book chapters, over 60 publications, and 100 invited lectures around the world, Inducted Fellow of the Society of Interventional Radiology. He holds M.D., University of Toronto; Radiology residency at University of British Columbia; Interventional radiology fellowship at Northwestern Memorial Hospital. In addition to bench side and clinical research in the fields of novel embolic platforms, ablative technologies and cancer-related thromboembolic disease, Dr. Liu maintains an interventional oncology practice incorporating multiple aspects of embolization, ablation, venous access, and palliative therapy in organ systems. Fluent in mandarin, Dr. Liu is an active member of the interventional radiology community and has served as an advisor on multiple global advisory boards and technology development committees for various scientific and commercial organizations. The Board believes Dr. Liu’s extensive industry experience, scientific credentials and active clinical practice provide him with vital insights into the trends, risks and opportunities in many of our core interests. Dr. Liu also contributes valuable clinical and industry perspective to the Board’s analysis of prospective acquisitions

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 347,170
Fiscal Year Total, USD 347,170

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Fred Lampropoulos

4,310,800

Raul Parra

--

Joseph Wright

943,467

Ronald Frost

1,082,820

Justin Lampropoulos

629,992

Brian Lloyd

1,183,020
As Of  31 Dec 2017